Financial Performance - The net loss for the three months ended September 30, 2023, was $16.6 million, a decrease of $1.6 million compared to a net loss of $18.2 million for the same period in 2022[101]. - The company incurred a net loss of $53.2 million for the nine months ended September 30, 2023, compared to a net loss of $54.0 million for the same period in 2022, reflecting a decrease of $0.8 million[106]. - The accumulated deficit reached $294.2 million as of September 30, 2023, with cash operating expenditures of $43.6 million for the nine months ended September 30, 2023, compared to $48.4 million in 2022[117]. Research and Development Expenses - Research and development expenses for the three months ended September 30, 2023, were $13.6 million, a slight decrease of $0.1 million from $13.7 million in the same period in 2022[102]. - Research and development expenses for the nine months ended September 30, 2023, totaled $42.5 million, an increase of $5.5 million from $37.0 million in the same period in 2022[107]. - The company expects significant increases in operating expenses as it advances product candidates through clinical development and seeks regulatory approval[90]. Cash and Financial Assets - As of September 30, 2023, total financial assets were $238.1 million, a decrease of $5.4 million from $243.5 million as of December 31, 2022[111]. - The company expects its cash, cash equivalents, and marketable securities as of September 30, 2023, to be sufficient to fund operations at least through 2025[117]. - As of September 30, 2023, the company had cash, cash equivalents, and marketable securities totaling $238.1 million, with restricted cash of $0.8 million[139]. Interest Income - Interest income, net for the three months ended September 30, 2023, was $3.0 million, an increase of $1.9 million compared to $1.1 million for the same period in 2022, driven by higher interest rates[105]. - Interest income, net rose to $8.0 million for the nine months ended September 30, 2023, an increase of $6.2 million compared to the same period in 2022, driven by higher interest rates[109]. Operating Activities - Cash used in operating activities was $43.6 million for the nine months ended September 30, 2023, down from $48.4 million in the same period of 2022[120]. - Total operating expenses for the nine months ended September 30, 2023, were $61.2 million, an increase of $5.4 million compared to $55.9 million for the same period in 2022[106]. Financing Activities - Financing activities generated $35.3 million in cash during the nine months ended September 30, 2023, mainly from the issuance of common stock under the ATM Program[125]. - The company has approximately $113.8 million remaining in gross proceeds available for future issuances of common stock under the ATM Program as of September 30, 2023[113]. Market Risks - The company is exposed to market risks primarily related to interest rate risks in the ordinary course of business[138]. - The company is not currently exposed to significant market risk related to changes in foreign currency exchange rates, but future contracts with foreign vendors may introduce such risks[140]. Stock-Based Compensation - Stock-based compensation expense is recognized on a straight-line basis over the associated service period of the award[132]. - The company uses the Black-Scholes option pricing model to estimate the fair value of stock options on the date of grant[134]. - Expected volatility for stock options is derived from the average historical stock volatility over the expected term of the awards[135]. Other Information - The company has not generated any revenue from product sales to date and does not expect to do so in the foreseeable future[94]. - The company plans to continue using third-party service providers for clinical development and manufacturing, as it does not currently have a sales force[92]. - The company engages vendors, CROs, and CMOs for preclinical development activities and clinical trials[133]. - Recent accounting pronouncements are detailed in Note 2 of the unaudited condensed financial statements for the nine months ended September 30, 2023[137].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3218129 (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3218129 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM ! 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39539 PMV PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-3218129 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3218129 (State or other jurisdiction of incorporation or organization) 8 Clarke Drive, Suite 3 Cranbury, NJ 08512 (Ad ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regula ...

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3218129 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM ! 10-K (Mark One) Delaware 46-3218129 (State or other jurisdiction of incorporation or organization) 8 Clarke Drive, Suite 3 Cranbury, NJ 08512 (Address of principal executive offices) (Zip Code) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSI ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3218129 (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3218129 (State or other jurisdi ...